Impact of pet on the radiation treatment of Hodgkin's lymphoma

Research output: Contribution to journalArticle

Abstract

Hodgkin's lymphoma (HL) is a lymphoproliferative malignancy that frequently affects young people. Because patients with HL are often cured, this neoplasm serves as a clinical laboratory for investigating the late effects of cancer therapy. The "hot" issues today are, in advanced stages, how to identify the best strategy to reduce the rate of resistant diseases and, in the early stages, how to minimize late toxicity due to both chemotherapy and radiotherapy (RT). Literature data revealed that PET as a very promising tool in the management of HL. The main applications of FDG-PET in HL are in staging, therapy monitoring, response assessing and follow-up. Recent data show that early PET seems to play a role in predicting the treatment outcome. In RT FDG-PET improves the accuracy in the disease localization and staging with changes in radiation treatment planning in one third of patients with early-stage HL. It also reduces the subjectivity in lymphoma RT field determination, one of the major causes of uncertainty in radiation treatments. The impact of FDG-PET will be greater as more conformal RT is planned. In conclusion, the highly curable early stage Hodgkin lymphomas require careful evaluation and balance of the available treatments, in order to achieve a really individualized solution, reducing radiation doses and/or fields dimension and using new advanced techniques.

Original languageEnglish
Pages (from-to)169-174
Number of pages6
JournalCurrent Radiopharmaceuticals
Volume2
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Pets
Hodgkin Disease
Radiation
Radiotherapy
Therapeutics
Conformal Radiotherapy
Neoplasms
Uncertainty
Lymphoma
Drug Therapy

Keywords

  • Fdg-pet
  • Hodgkin's lymphoma
  • Imrt
  • Radiation therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pharmacology

Cite this

Impact of pet on the radiation treatment of Hodgkin's lymphoma. / Versari, Annibale; Iotti, Cinzia; Merli, Francesco.

In: Current Radiopharmaceuticals, Vol. 2, No. 3, 2009, p. 169-174.

Research output: Contribution to journalArticle

@article{62bf0df30f6c4a70ad438d535716d500,
title = "Impact of pet on the radiation treatment of Hodgkin's lymphoma",
abstract = "Hodgkin's lymphoma (HL) is a lymphoproliferative malignancy that frequently affects young people. Because patients with HL are often cured, this neoplasm serves as a clinical laboratory for investigating the late effects of cancer therapy. The {"}hot{"} issues today are, in advanced stages, how to identify the best strategy to reduce the rate of resistant diseases and, in the early stages, how to minimize late toxicity due to both chemotherapy and radiotherapy (RT). Literature data revealed that PET as a very promising tool in the management of HL. The main applications of FDG-PET in HL are in staging, therapy monitoring, response assessing and follow-up. Recent data show that early PET seems to play a role in predicting the treatment outcome. In RT FDG-PET improves the accuracy in the disease localization and staging with changes in radiation treatment planning in one third of patients with early-stage HL. It also reduces the subjectivity in lymphoma RT field determination, one of the major causes of uncertainty in radiation treatments. The impact of FDG-PET will be greater as more conformal RT is planned. In conclusion, the highly curable early stage Hodgkin lymphomas require careful evaluation and balance of the available treatments, in order to achieve a really individualized solution, reducing radiation doses and/or fields dimension and using new advanced techniques.",
keywords = "Fdg-pet, Hodgkin's lymphoma, Imrt, Radiation therapy",
author = "Annibale Versari and Cinzia Iotti and Francesco Merli",
year = "2009",
doi = "10.2174/1874471010902030169",
language = "English",
volume = "2",
pages = "169--174",
journal = "Current Radiopharmaceuticals",
issn = "1874-4710",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Impact of pet on the radiation treatment of Hodgkin's lymphoma

AU - Versari, Annibale

AU - Iotti, Cinzia

AU - Merli, Francesco

PY - 2009

Y1 - 2009

N2 - Hodgkin's lymphoma (HL) is a lymphoproliferative malignancy that frequently affects young people. Because patients with HL are often cured, this neoplasm serves as a clinical laboratory for investigating the late effects of cancer therapy. The "hot" issues today are, in advanced stages, how to identify the best strategy to reduce the rate of resistant diseases and, in the early stages, how to minimize late toxicity due to both chemotherapy and radiotherapy (RT). Literature data revealed that PET as a very promising tool in the management of HL. The main applications of FDG-PET in HL are in staging, therapy monitoring, response assessing and follow-up. Recent data show that early PET seems to play a role in predicting the treatment outcome. In RT FDG-PET improves the accuracy in the disease localization and staging with changes in radiation treatment planning in one third of patients with early-stage HL. It also reduces the subjectivity in lymphoma RT field determination, one of the major causes of uncertainty in radiation treatments. The impact of FDG-PET will be greater as more conformal RT is planned. In conclusion, the highly curable early stage Hodgkin lymphomas require careful evaluation and balance of the available treatments, in order to achieve a really individualized solution, reducing radiation doses and/or fields dimension and using new advanced techniques.

AB - Hodgkin's lymphoma (HL) is a lymphoproliferative malignancy that frequently affects young people. Because patients with HL are often cured, this neoplasm serves as a clinical laboratory for investigating the late effects of cancer therapy. The "hot" issues today are, in advanced stages, how to identify the best strategy to reduce the rate of resistant diseases and, in the early stages, how to minimize late toxicity due to both chemotherapy and radiotherapy (RT). Literature data revealed that PET as a very promising tool in the management of HL. The main applications of FDG-PET in HL are in staging, therapy monitoring, response assessing and follow-up. Recent data show that early PET seems to play a role in predicting the treatment outcome. In RT FDG-PET improves the accuracy in the disease localization and staging with changes in radiation treatment planning in one third of patients with early-stage HL. It also reduces the subjectivity in lymphoma RT field determination, one of the major causes of uncertainty in radiation treatments. The impact of FDG-PET will be greater as more conformal RT is planned. In conclusion, the highly curable early stage Hodgkin lymphomas require careful evaluation and balance of the available treatments, in order to achieve a really individualized solution, reducing radiation doses and/or fields dimension and using new advanced techniques.

KW - Fdg-pet

KW - Hodgkin's lymphoma

KW - Imrt

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=77953770972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953770972&partnerID=8YFLogxK

U2 - 10.2174/1874471010902030169

DO - 10.2174/1874471010902030169

M3 - Article

AN - SCOPUS:77953770972

VL - 2

SP - 169

EP - 174

JO - Current Radiopharmaceuticals

JF - Current Radiopharmaceuticals

SN - 1874-4710

IS - 3

ER -